CD4 | CD molecules | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

CD4

Target id: 2995

Nomenclature: CD4

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD4 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 458 12p13.31 CD4 CD4 molecule
Mouse 1 457 6 F2; 6 59.17 cM Cd4 CD4 antigen
Rat 1 457 4q42 Cd4 Cd4 molecule
Gene and Protein Information Comments
Multiple alternatively spliced transcript variants encoding different isoforms have been identified in the human CD4 gene.
Previous and Unofficial Names
CD4 antigen (p55) | T-cell surface glycoprotein CD4 | cluster of differentiation 4
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
tregalizumab Hs Binding - - 11
[11]
General Comments
CD4 is a cell membrane-bound glycoprotein that belongs to the immunoglobulin superfamily of proteins. It plays an essential role in the immune response. CD4's major function is as a co-receptor of the T cell receptor (TCR), which facilitates TCR interaction with MHC class II molecule:antigen complexes on antigen presenting cells, which subsequently leads to activation of T helper cells and production/release of immune system modulators. The intracellular cytoplasmic tail of ligand-engaged CD4 recruits the tyrosine kinase Lck to initiate the signalling cascade that culminates in immune system modulation. CD4 is also the primary receptor for the human immunodeficiency virus-1 (HIV-1) envelope protein gp120, and this ligand-receptor interaction facilitates recruitment of additional co-receptors (CCR5 or CXCR4) which are required for viral infection of T cells.

References

Show »

1. Duan LW, Zhang H, Zhao MT, Sun JX, Chen WL, Lin JP, Liu XQ. (2017) A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. Sci Rep, 7: 46733. [PMID:28429756]

2. Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. (2018) Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N. Engl. J. Med., 379 (7): 645-654. [PMID:30110589]

3. Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B et al.. (2015) A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol. Cell Biol., 93 (4): 396-405. [PMID:25512343]

4. Iacob SA, Iacob DG. (2017) Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy. Front Microbiol, 8: 2323. [PMID:29230203]

5. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R et al.. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 109 (11): 4655-62. [PMID:17311990]

6. Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC, Larché M, Kay AB. (2001) The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur. Respir. J., 18 (1): 45-52. [PMID:11510804]

7. König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J. (2016) Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol, 7: 11. [PMID:26834751]

8. Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C. (2008) Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opin Biol Ther, 8 (12): 1929-39. [PMID:18990079]

9. van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R et al.. (2018) Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Ann. Rheum. Dis., 77 (4): 495-499. [PMID:29343509]

10. Villadsen LS, Skov L, Dam TN, Dagnaes-Hansen F, Rygaard J, Schuurman J, Parren PW, van de Winkel JG, Baadsgaard O. (2007) In situ depletion of CD4+ T cells in human skin by Zanolimumab. Arch. Dermatol. Res., 298 (9): 449-55. [PMID:17091277]

11. Wijdenes J. (2004) Humanized anti-cd4 antibody with immunosuppressive properties. Patent number: WO2004083247 A1. Assignee: Biotest Ag. Priority date: 21/03/2003. Publication date: 30/09/2004.

How to cite this page

CD molecules: CD4. Last modified on 05/09/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2995.